Multicomponent therapeutics for networked systems

Nature Reviews Drug Discovery

Volumn 4, Issue 1, 2005, Pages 71-78

  Keith, Curtis T ^a   Borisy, Alexis A ^a   Stockwell, Brent R ^b  

^a Department of Preclinical Development and Formulations   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMOXICILLIN PLUS CLAVULANIC ACID; CHLORPROMAZINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPYRIDAMOLE; DOXORUBICIN; DRUG; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOVASTATIN PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PENTAMIDINE; PLACEBO; PREDNISONE; SALMETEROL; SODIUM CHLORIDE; VINCRISTINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ARTICLE; ASTHMA; CANCER COMBINATION CHEMOTHERAPY; CHEMICAL COMPOSITION; COMPUTER MODEL; DRUG ACTIVITY; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESEARCH; EXPERIMENTAL MODEL; FORCED EXPIRATORY VOLUME; GROWTH INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; INFORMATION SYSTEM; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR GROWTH;

CLINICAL TRIALS; DRUG DESIGN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; TERMINOLOGY;

EID: 12144258457     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1609     Document Type: Article

References (64)

1. Reich, D. E. & Lander, E. S. On the allelic spectrum of human disease. Trends Genet. 17, 502-510 (2001).
2. Loktionov, A. Common gene polymorphisms and nutrition: emerging links with pathogenesis of multifactorial chronic diseases. J. Nutr. Biochem. 14, 426-451 (2003).
3. Kaplan, J. C. & Junien, C. Genomics and medicine: an anticipation. From Boolean Mendelian genetics to multifactorial molecular medicine. CR Acad. Sci. III 323, 1167-1174 (2000).
4. Kitano, H. Systems biology: a brief overview. Science 295, 1662-1664 (2002).
5. Ideker, T., Galitski, T. & Hood, L. A new approach to decoding life: systems biology. Annu. Rev. Genomics Hum. Genet. 2, 343-372 (2001).
6. Lee, T. I. et al. Transcriptional regulatory networks in Saccharomyces cerevisiae. Science 298, 799-804 (2002).
7. Brent, R. Genomic biology. Cell 100, 169-183 (2000).
8. Blume-Jensen, P. & Hunter, T. Oncogenic kinase signalling. Nature 411, 355-365 (2001).
9. Humbert, S. et al. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev. Cell 2, 831-837 (2002).
10. Banerjee, N. & Zhang, M. Q. Functional genomics as applied to mapping transcription regulatory networks. Curr. Opin. Microbiol. 5, 313-317 (2002).
11. Pilpel, Y., Sudarsanam, P. & Church, G. M. Identifying regulatory networks by combinatorial analysis of promoter elements. Nature Genet. 29, 153-159 (2001).
12. Arteaga, C. L. Molecular therapeutics: is one promiscuous drug against multiple targets better than combinations of molecule-specific drugs? Clin. Cancer Res. 9, 1231-1232 (2003).
13. Chabner, B. A. Promising new drugs and combinations. Fulfilling our pledge. Oncologist 4, VIII (1999).
14. Stupp, R. & R. egg, C. New drugs and combinations for malignant glioma. Forum (Genova) 13, 61-75 (2003).
15. Mondimore, F. M., Fuller, G. A. & DePaulo, J. R. Drug combinations for mania. J. Clin. Psychiatry 64 (Suppl. 5), 25-31 (2003).
16. Danis, M. & Bricaire, F. The new drug combinations: their place in the treatment of uncomplicated Plasmodium falciparum malaria. Fundam. Clin. Pharmacol. 17, 155-160 (2003).
17. Curatolo, M. & Sveticic, G. Drug combinations in pain treatment: a review of the published evidence and a method for finding the optimal combination. Best Pract. Res. Clin. Anaesthesiol. 16 507-519 (2002).
18. Pirker R. Two- versus three-drug combinations in the chemotherapy of advanced non-small-cell lung cancer. Lung Cancer 38 (Suppl. 3), S53-S55 (2002).
19. Maga, G. & Spadari, S. Combinations against combinations: associations of anti-HIV 1 reverse transcriptase drugs challenged by constellations of drug resistance mutations. Curr. Drug Metab. 3 73-95 (2002).
20. Hainsworth, J. D., Burris, H. A. & Greco, F. A. Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: a review of the Sarah Cannon Cancer Center experience. Semin. Oncol. 28, 43-47 (2001).
21. Yuan, R. & Lin, Y. Traditional Chinese medicine: an approach to scientific proof and clinical validation. Pharmacol. Ther. 86 191-8 (2000).
22. Foungbe, S., Kouassi, G., Kablan, J. B. & Marcy, R. Study of Costus lucanusianus: plant juice, fraction combinations and pharmacologic estimation of natural product total activity. J. Ethnopharmacol. 33, 221-226 (1991).
23. Turner, D. M. Natural product source material use in the pharmaceutical industry: the Glaxo experience. J. Ethnopharmacol. 51, 39-43; discussion 44 (1996).
24. Schuster, B. G. A new integrated program for natural product development and the value of an ethnomedical approach. J. Altern. Complement. Med. 7 (Suppl. 1), S61-S72 (2001).
25. Fraser, T. R. An experimental research on the antagonism between the actions of physostigma and atropia. Proc. R. Soc. Edinburgh 7, 506 (1871).
26. Loewe, S. Die quantitation probleme der pharmakologie. Ergebn. Physiol. 27, 47-187 (1928).
27. Loewe, S. The problem of synergism and antagonism of combined drugs. Arzneimitteforsch 3, 285 (1953).
28. Ehrlich, P. Chemotherapeutics: scientific principles, methods and results. Lancet 2, 445-451 (1913).
29. Albert, A. Selective Toxicity (Methuen & Co., London, 1968).
30. Kinzler, K. W. & Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 87, 159-170 (1996).
31. DeVita, V. T. in Cancer: Principles and Practice of Oncology (eds DeVita, V. T., Hellman, S. & Rosenberg, S. A.) 333-347 (Lippincott-Raven, Philadelphia, 1997).
32. Nelson, H. S. Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma. J. Allergy Clin. Immunol. 107, 398-416 (2001).
33. Kavuru, M. et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J. Allergy Clin. Immunol. 105, 1108-1116 (2000).
34. Gupta, E. K. & Ito, M. K. Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia. Heart Dis. 4, 124-137 (2002).
35. Black, D. M. The development of combination drugs for atherosclerosis. Curr. Atheroscler. Rep. 5, 29-32 (2003).
36. Bays, H. E. et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am. J. Cardiol. 91, 667-672 (2003).
37. Larder, B. A., Kemp, S. D. & Harrigan, P. R. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269, 696-699 (1995).
38. Grodeck, B. AZT plus 3TC produces best results to date. Posit Aware, 6 (1995).
39. Knoben, J. E., Scott, G. R. & Tonelli, R. J. An overview of the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations. Am. J. Hosp. Pharm. 47, 2696-2700 (1990).
40. Greco, W. R., Bravo, G. & Parsons, J. C. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47, 331-385 (1995).
41. Chou, T.-C. & Talalay, P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol. Sci. 4, 450-454 (1983).
42. Chou, T.-C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 35, 27 (1984).
43. Bliss, C. I. The toxicity of poisons applied jointly. Ann. Appl. Biol. 26, 585-615 (1939).
44. Groten, J. P. Toxicology of simple and complex mixtures. Trends Pharmacol. Sci. 22, 316-322 (2001).
45. Stein, G. E. & Gurwith, M. J. Amoxicillin-potassium clavulanate, a β-lactamase-resistant antibiotic combination. Clin. Pharmacy 3, 591-599 (1984).
46. Hartman, J. L. T., Garvik, B. & Hartwell, L. Principles for the buffering of genetic variation. Science 291, 1001-1004 (2001).
47. Guarente, L. Synthetic enhancement in gene interaction: a genetic tool come of age. Trends Genet. 9, 362-366 (1993).
48. Tong, A. H. et al. Systematic genetic analysis with ordered arrays of yeast deletion mutants. Science 294, 2364-2368 (2001).
49. Schoebert, B., Eichler-Jonsson, C., Gilles, E. D. & Muller, G. Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nature Biotechnol. 20, 370-375 (2002).
50. Hopkins, A. L. & Groom, C. R. Target analysis: a priori assessment of druggability. Ernst Schering Res. Found Workshop, 11-17 (2003).
51. Stockwell, B. R. Chemical genetics: ligand-based discovery of gene function. Nature Rev. Genet. 1, 116-125 (2000).
52. Stockwell, B. R. Frontiers in chemical genetics. Trends Biotechnol. 18, 449-455 (2000).
53. Stockwell, B. R. Chemical genetic screening approahces to neurobiology. Neuron 36, 559-562 (2002).
54. Markham, P. N., Westhaus, E., Klyachko, K., Johnson, M. E. & Neyfakh, A. A. Multiple novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus. Antimicrob. Agents Chemother. 43, 2404-2408. (1999).
55. Borisy, A. A. et al. Systematic discovery of multicomponent therapeutics. Proc. Natl Acad. Sci. USA 1000, 7977-7982 (2003).
56. Marschall, M., Freitag, M., Weiler, S., Sorg, G. & Stamminger, T. Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents. Antimicrob. Agents Chemother. 44, 1588-1597 (2000).
57. Dolma, S., Lessnick, S. L., Hahn, W. C. & Stockwell, B. R. Identification of genotype-selective antitumor agents using synthetic lethal chemical screeening in engineered human tumor cells. Cancer Cell 3, 285-296 (2003).
58. Root, D. E., Flaherty, S. P., Kelley, B. P. & Stockwell, B. R. Biological mechanism profiling using an annotated compound library. Chem. Biol. 10, 881-892 (2003).
59. Blanchard, B. J., Stockwell, B. R., & Ingram, V. M. Eliminating membrane depolarization caused by the Alzheimer peptide Aβ(1-42, aggr.). Biochem. Biophys. Res. Commun. 293, 1204-1208 (2002).
60. Nakayama, T., Honda, K., Omura, H. & Hayashi, N. Oviposition stimulants for the tropical swallowtail butterfly, Papilio polytes, feeding on a rutaceous plant, Toddalia asiastica. J. Chem. Ecol. 29, 1621-1634 (2003).
61. Stermitz, F. R., Lorenz, P., Tawara, J. N., Zenewicz, L. A. & Lewis, K. Synergy in a medical plant: antimicrobial action of berberine potentiated by 5′-methoxy-hydnocarpin, a multidrug pump inhibitor. Proc. Natl Acad. Sci. USA 97, 1433-1437 (2000).
62. Keeling, C. I., Slessor, K. N., Higo, H. A. & Winston, M. L. New components of the honey bee (Apis mellifera L.) queen retinue pheromone. Proc. Natl Acad. Sci. USA 100, 4486-4491 (2003).
63. Belardelli, F. Role of interferons and other cytokinase in the regulation of the immune response. Apmis 103, 161-179 (1995).
64. Wan, Y. & Bramson, J. Role of dendritic cell-derived cytokines in immune regulation. Curr. Pharm. Des. 7, 977-992 (2001).